Trajan Signs Agreement with GenTegra to Distribute RNA Stabilization Solution for Mitra-VAMS Microsampling
PLEASANTON, Calif. and TORRANCE, Calif., Nov. 28, 2023 /PRNewswire-PRWeb/ -- Trajan Scientific and Medical (Trajan), a global developer and manufacturer of analytical and life sciences products, today announced they have signed an agreement with GenTegra, an innovator of biological sample protection solutions, to distribute the GenTegraRNA-NEO Active Chemical Protection™ technology. GenTegra's protection solution, designed exclusively for Trajan, can be applied to Trajan's Neoteryx Mitra® microsampling devices based on VAMS® technology for RNA-based studies. Once treated, the devices are intended to provide researchers with high-quality RNA recovery from remote blood microsamples that don't require cold-shipping or storage for up to 7 days before extraction. The GenTegraRNA-NEO technology protects against naturally occurring nucleases and environmental stresses that could degrade the RNA in blood samples.
- GenTegra's protection solution, designed exclusively for Trajan, can be applied to Trajan's Neoteryx Mitra® microsampling devices based on VAMS® technology for RNA-based studies.
- "GenTegra is proud to collaborate with Trajan in introducing the GenTegraRNA-NEO Active Chemical Protection™ technology, exclusively tailored for Neoteryx Mitra® microsampling devices," said Robert (Bob) Barrett, President, GenTegra.
- "GenTegra is proud to collaborate with Trajan in introducing the GenTegraRNA-NEO Active Chemical Protection™ technology, exclusively tailored for Neoteryx Mitra® microsampling devices," said Robert (Bob) Barrett, President, GenTegra.
- "The overwhelmingly positive feedback from early users reinforces the impact of GenTegraRNA-NEO technology coupled with Mitra microsampling devices."